Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment

被引：32
作者：
Onesti, Concetta Elisa [1 ,2 ,3 ]
Freres, Pierre [2 ]
Jerusalem, Guy [2 ,3 ]
机构：
[1] Univ Liege, GIGA Res Inst, Lab Human Genet, Liege, Belgium
[2] CHU Liege, Univ Hosp, Dept Med Oncol, Ave Hop 1, B-4000 Liege, Belgium
[3] Univ Liege, GIGA Res Inst, Lab Med Oncol, Liege, Belgium
来源：
JOURNAL OF THORACIC DISEASE | 2019年 / 11卷 / 01期
关键词：
IPILIMUMAB; NIVOLUMAB; DOCETAXEL;
D O I：
10.21037/jtd.2018.12.47
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：35 / 38
页数：4
相关论文
共 50 条
  • [1] Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review
    Michalarea, Vasiliki
    Fontana, Elisa
    Garces, Alvaro Ingles
    Williams, Anja
    Smyth, Elizabeth C.
    Picchia, Simona
    Rao, Sheela
    Chau, Ian
    Cunningham, David
    Bali, Maria Antonietta
    CURRENT PROBLEMS IN CANCER, 2019, 43 (05) : 487 - 494
  • [2] Decision-making for the clinical Practice: Current Concepts and Treatment Algorithms with Immune Checkpoint Inhibitors for Melanoma
    Schadendorf, Dirk
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 8 - 12
  • [3] Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors
    Xie, Yumo
    Lin, Jinxin
    Zhang, Ning
    Wang, Xiaolin
    Wang, Puning
    Peng, Shaoyong
    Li, Juan
    Wu, Yuanhui
    Huang, Yaoyi
    Zhuang, Zhuokai
    Shen, Dingcheng
    Zhu, Mingxuan
    Liu, Xiaoxia
    Liu, Guangjian
    Meng, Xiaochun
    Huang, Meijin
    Yu, Huichuan
    Luo, Yanxin
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (02): : 133 - +
  • [4] PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
    Gabrys, H. S.
    Basler, L.
    Burgermeister, S.
    Hogan, S.
    Ahmadsei, M.
    Pavic, M.
    Bogowicz, M.
    Vuong, D.
    Tanadini-Lang, S.
    Foerster, R.
    Kudura, K.
    Huellner, M.
    Dummer, R.
    Levesque, M. P.
    Guckenberger, M.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
    Won, Sang Eun
    Park, Hyo Jung
    Byun, Sangil
    Pyo, Junhee
    Kim, Jwa Hoon
    Choi, Chang-Min
    Lee, Jae Cheol
    Lee, Dae Ho
    Kim, Sang-We
    Yoon, Shinkyo
    Kim, Kyung Won
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [6] Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition
    Li, Yikun
    Wang, Peiliang
    Xu, Junhao
    Shi, Xiaonan
    Yin, Tianwen
    Teng, Feifei
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [7] Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
    Duffy, Michael J.
    Crown, John
    CLINICAL CHEMISTRY, 2019, 65 (10) : 1228 - 1238
  • [8] Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
    Brahmer, Julie R.
    Pardoll, Drew M.
    CANCER IMMUNOLOGY RESEARCH, 2013, 1 (02) : 85 - 91
  • [9] Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients
    Liu, Jing
    Ma, Jingtao
    Xing, Na
    Ji, Zhengzheng
    Li, Jiasong
    Zhang, Shasha
    Guo, Zhanjun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3043 - 3050
  • [10] Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors
    Abbar, B.
    Castelbajac, V. De
    Gougis, P.
    Assoun, S.
    Pluvy, J.
    Tesmoingt, C.
    Theou-Anton, N.
    Cazes, A.
    Namour, C.
    Khalil, A.
    Gounant, V.
    Besse, B.
    Zalcman, G.
    Brosseau, S.
    LUNG CANCER, 2021, 152 : 109 - 118
12345